 |
|||
|
Innovative products for cancer and AIDS treatment
The “Drug Resistance Company” focuses its R&D on oncology, infectiology, AIDS. Recently brought to the market a phenotypic HIV test and one therapeutic product. Other products in clinical stage. IPO in December 2005 on EuroNext. |
News :
BioAlliance Pharma announces... BioAlliance Pharma announces Q3 2007 results -Specialty pharma announces very strong growth in...
Read more  PDF FileSuccess stories : BioAlliance succeeds in its IPO on EuroNext Paris
> See the press release |
||